September 5, 2017 06:29 AM EDT
Deals
Pharma

Em­bold­ened by re­cent R&D suc­cess­es, Mer­ck KGaA looks at sell­ing off $1B-plus con­sumer di­vi­sion

John Carroll

Editor & Founder

En­cour­aged by two no­table drug ap­provals af­ter a long Siber­ian win­ter of fail­ures and set­backs, Mer­ck KGaA has very pub­licly post­ed a ‘for sale …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times